Questions we're asking
See all our research
Why does chemotherapy stop working?
Most patients with high-grade serous ovarian cancer respond to first-line platinum chemotherapy — then relapse with disease that no longer responds. We're mapping the cell states that survive treatment and tracking how they re-emerge.
Treatment resistance
Can we make ovarian cancer respond to immunotherapy?
The ovarian tumour microenvironment is profoundly immunosuppressive, leaving checkpoint inhibitors and other immunotherapies largely ineffective. We're developing new therapeutics to reprogram the TME and unleash a durable anti-tumour response.
Novel immunotherapies
How does endometriosis become cancer?
Women with endometriosis face 2–3× the risk of ovarian cancer. We're tracing the cellular transitions from benign lesion to malignant transformation — catching the process before it progresses.
ProgressionLatest
- Preprint · 2026 Our new preprint on how tumour architecture shapes malignant phenotypes in HGSC is available online
- New members · 2026 Welcome Sara, Michelle, Katrina, and Elizabeth to the lab!
- Publication · 2025 New collaborative study published in Nature Biotechnology exploring best practices in spatial genomics
- Funding · 2025 CIHR Project Grant awarded — targeting malignant cell states in ovarian cancer
- Funding · 2025 Cook Lab joins $6.5M CCS Breakthrough Team Grant on ovarian cancer dormancy
- Funding · 2025 CIHR Project Grant awarded — racial and ethnic disparities in endometriosis